AAV Production Yield Calculator
1Serotype Preset
Cell Density at Transfection (x106 cells/mL) ?
Culture Volume (L)
Specific Yield (vg/cell) ?
2Purification Steps ?
3Full:Empty Capsid Ratio
20%
5% (mostly empty)90% (highly enriched)
Dose (vg/kg) ?
Custom Dose (vg/kg)
Patient Weight (kg)
Overfill (%) ?
5Cost Inputs (per batch)
Plasmid DNA ($/mg)
Transfection Reagent ($/L)
Media ($/L)
Affinity Resin ($/L resin)
0
total vg
Final Purified Yield
--
Overall Recovery
--
Doses / Batch
--
Cost / Dose
4Yield Waterfall
Remaining vg Loss at step
Cumulative Yield Curve
Step-by-Step Results
Dose Output
Scale Comparison
5Cost Estimate

About AAV Production Yield Estimation

Adeno-associated virus (AAV) vectors are the leading delivery platform for in vivo gene therapies, with over 200 clinical trials and several approved products including Zolgensma, Luxturna, and Hemgenix. Manufacturing AAV at clinical and commercial scale requires careful tracking of viral genome (vg) yield through every process step, from upstream cell culture and transfection through downstream purification to final formulation. This calculator estimates total vg output and per-dose economics for HEK293 triple-transfection processes, the most widely used production platform.

The key formula is straightforward: crude harvest vg = cell density (cells/mL) x culture volume (mL) x specific yield (vg/cell). Each downstream step (harvest, clarification, affinity chromatography, ion exchange polishing, UF/DF, and sterile filtration) applies a recovery factor, giving overall purification yields of 20-50%. The full:empty capsid ratio, typically 10-30% full for classical triple transfection, determines what fraction of capsids carry the therapeutic transgene. AEX polishing enriches this ratio but at the cost of yield loss. Therapeutic doses range from 10¹¹ vg/eye for intravitreal indications to 10¹⁴ vg/kg for systemic delivery, making dose-dependent manufacturing economics critical for commercial viability.

This tool pairs with the AAV Titer Unit Converter for unit conversions between vg/mL, GC/mL, capsids/mL, and TU/mL. For more context on optimizing each step, see the AAV Production Yield guide and AAV Downstream Processing article.

Related Articles

AAV Production Yield
Titer, vg/cell, and how to improve it
AAV Downstream Processing
Purification strategies and yield optimization
AAV Titer Units Explained
vg/mL, GC/mL, capsids, and TU conversions
AAV Titer Unit Converter
Convert between vg/mL, GC/mL, capsids, and TU

Further Reading

Frequently Asked Questions

What is a typical AAV production yield in vg per cell?

Typical AAV yields from HEK293 triple transfection range from 1 x 10⁴ to 5 x 10⁵ vg/cell depending on serotype, plasmid design, and process conditions. AAV2 commonly yields 1-5 x 10⁴ vg/cell, while AAV8 and AAV9 can reach 1-5 x 10⁵ vg/cell under optimized conditions. Stable producer cell lines and baculovirus-insect cell systems may achieve higher per-cell yields but require longer development timelines.

How do I calculate total AAV yield from a production batch?

Total crude harvest yield (vg) = cell density at transfection (cells/mL) x culture volume (mL) x specific yield (vg/cell). For example, 1.5 x 10⁶ cells/mL x 10,000 mL (10L) x 1 x 10⁵ vg/cell = 1.5 x 10¹⁵ total vg. The purified yield is then calculated by multiplying crude yield by the recovery percentage at each downstream step.

What is a typical overall purification recovery for AAV?

Overall AAV purification recovery from crude harvest to final bulk typically ranges from 20-50%. A typical 6-step process (harvest/lysis at 90%, clarification at 90%, affinity at 75%, AEX polishing at 80%, UF/DF at 90%, sterile filtration at 97%) gives approximately 40% overall recovery. The affinity chromatography step is usually the largest single yield loss.

How many patient doses can one AAV batch produce?

The number of doses per batch depends on the final purified vg yield and the therapeutic dose. For a low-dose intravitreal indication (1 x 10¹¹ vg/eye), a 50L bioreactor batch might produce thousands of doses. For a high-dose systemic indication like SMA (1.1 x 10¹⁴ vg/kg for a 10 kg child), the same batch might produce only 5-15 doses.

What is the full:empty capsid ratio and why does it matter?

The full:empty ratio describes what fraction of AAV capsids contain the therapeutic transgene DNA. Typical ratios from HEK293 triple transfection are 10-30% full capsids. Empty capsids are immunogenic but not therapeutic, so regulatory agencies require characterization and often enrichment. AEX polishing can enrich the ratio to 50-80% full. AUC and CDMS are the standard analytical methods.

What are the main cost drivers in AAV manufacturing?

The primary cost drivers are plasmid DNA ($50-200/mg at GMP grade, requiring 1-2 mg per liter of culture), transfection reagent ($20-100/L), serum-free media ($30-80/L), and affinity chromatography resin ($5,000-15,000 per liter of resin). At small scale, consumable costs can reach $100,000-500,000 per batch. At larger scale, fixed costs (facility, QC testing, labor) dominate.